Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.093
Neutral
RSI(14)
70.298
Buy
STOCH(KDJ)(9,3,3)
53.711
Neutral
ATR(14)
0.234
High Vlolatility
CCI(14)
103.408
Buy
Williams %R
39.130
Buy
TRIX(12,20)
0.630
Sell
StochRSI(14)
0.756
Oversold
Verona Pharma PLC
VRNAView Detailed Chart
105.140USD
-0.030-0.03%
Close 07/30, 16:00（ET）Quotes delayed by 15 min
71.61BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.03%
5 Days
+0.18%
1 Month
+11.17%
6 Months
+83.68%
Year to Date
+126.40%
1 Year
+377.26%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
12
analysts
HOLD
Current Rating
106.300
Target Price
1.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
553
Total
5
Median
6
Average
Company name
Ratings
Analysts
Verona Pharma PLC
VRNA
12
CRISPR Therapeutics AG
CRSP
29
Intellia Therapeutics Inc
NTLA
28
Exact Sciences Corp
EXAS
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
111
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Buy
Moving Average
Indicators
Value
Direction
MA5
105.140
Sell
MA10
105.024
Buy
MA20
101.927
Buy
MA50
92.368
Buy
MA100
78.198
Buy
MA200
62.477
Buy
News
Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact
TradingKey - U.S. pharmaceutical giant Merck (MRK.US) has announced a roughly $10 billion deal to acquire U.K.-based biopharma firm Verona Pharma (VRNA.US), marking a major move into the respiratory disease treatment space.
TradingKeyThu, Jul 10
Merck to Acquire Verona for $10 Billion — A Major Move into Respiratory Care, Shares of VRNA Surge 20%
TradingKey - According to a report by the Financial Times, U.S. pharmaceutical giant Merck (MRK.US) is nearing a deal to acquire Verona Pharma (VRNA.US) for $10 billion, marking Merck’s largest biopharma acquisition since 2023. The acquisition will expand Merck’s presence in the respiratory disease
TradingKeyWed, Jul 9
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Ticker SymbolVRNA
CompanyVerona Pharma PLC
CEODr. David S. Zaccardelli, Pharm.D.
Websitehttps://www.veronapharma.com/
Related Instruments
+0.02%
-1.55%
-1.90%
-1.28%
-0.30%
+0.17%
-2.00%
-2.26%
-0.98%
+2.12%
-0.82%
-0.23%
-0.28%
-2.91%
-1.56%
-1.27%
+0.14%
-0.88%
+3.89%
+4.56%
